[{"id":"126c7d05-be8d-4cf8-b5ca-fc8327c8dac0","acronym":"GEM","url":"https://clinicaltrials.gov/study/NCT06085677","created_at":"2023-10-17T15:12:32.611Z","updated_at":"2024-07-02T16:35:33.338Z","phase":"","brief_title":"The Gastric HormonE BioMarkers of Preneoplastic Lesions Study","source_id_and_acronym":"NCT06085677 - GEM","lead_sponsor":"Imperial College London","biomarkers":" GAST","pipe":"","alterations":" ","tags":["GAST"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/04/2023","start_date":" 11/04/2023","primary_txt":" Primary completion: 09/02/2024","primary_completion_date":" 09/02/2024","study_txt":" Completion: 09/02/2024","study_completion_date":" 09/02/2024","last_update_posted":"2023-10-17"},{"id":"1c7411aa-3958-4e55-a6f9-57809423a865","acronym":"CLARINET FORTE","url":"https://clinicaltrials.gov/study/NCT02651987","created_at":"2021-01-18T12:54:41.991Z","updated_at":"2024-07-02T16:36:03.082Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg","source_id_and_acronym":"NCT02651987 - CLARINET FORTE","lead_sponsor":"Ipsen","biomarkers":" SSTR • GAST • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • GAST • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/24/2019","study_completion_date":" 10/24/2019","last_update_posted":"2022-10-03"},{"id":"0b3e4665-fbf8-4ba7-a3d6-278bb6c2a88f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04198051","created_at":"2021-01-18T20:27:30.344Z","updated_at":"2024-07-02T16:36:52.524Z","phase":"","brief_title":"The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon Cancer","source_id_and_acronym":"NCT04198051","lead_sponsor":"The First Affiliated Hospital of Dalian Medical University","biomarkers":" IL6 • TNFA • CD4 • GAST","pipe":"","alterations":" ","tags":["IL6 • TNFA • CD4 • GAST"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin"],"overall_status":"Unknown status","enrollment":" Enrollment 120","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 12/20/2020","primary_completion_date":" 12/20/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-12-13"},{"id":"e5707a5c-1d4f-4dd4-b95e-4a1bae677f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT01339169","created_at":"2021-01-18T05:27:48.969Z","updated_at":"2024-07-02T16:36:56.829Z","phase":"Phase 2","brief_title":"YF476 and Type I Gastric Carcinoids","source_id_and_acronym":"NCT01339169","lead_sponsor":"Trio Medicines Ltd.","biomarkers":" GAST","pipe":"","alterations":" ","tags":["GAST"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e netazepide (YF476)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/04/2011","start_date":" 01/04/2011","primary_txt":" Primary completion: 12/10/2013","primary_completion_date":" 12/10/2013","study_txt":" Completion: 12/10/2013","study_completion_date":" 12/10/2013","last_update_posted":"2019-08-19"},{"id":"1e5999e2-4178-4034-931d-a4d5cc3d8186","acronym":"","url":"https://clinicaltrials.gov/study/NCT03812939","created_at":"2021-01-18T18:50:39.177Z","updated_at":"2024-07-02T16:37:03.582Z","phase":"","brief_title":"Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs","source_id_and_acronym":"NCT03812939","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" SSTR • GAST","pipe":"","alterations":" ","tags":["SSTR • GAST"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2019-01-23"},{"id":"5d3cfcae-967f-405e-a07b-79cc456de27b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01322542","created_at":"2021-01-18T05:23:03.070Z","updated_at":"2024-07-02T16:37:17.025Z","phase":"Phase 2","brief_title":"YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome","source_id_and_acronym":"NCT01322542","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" GAST","pipe":"","alterations":" ","tags":["GAST"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e netazepide (YF476)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-10-18"}]